The expression of βII makes them susceptible to treatment with anti-tumor drugs such as taxol and vinblastine (Derry et al., 1997; Khan and Ludueña, 2003), but cancers can often escape that by making more βIII (Mozzetti et al., 2005). This evidence concerns the gene CACNA1B and neoplasm.